ANX-188 Thorough QT/QTc Study in Healthy Volunteers
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study has been designed in compliance with the ICH-E14 guideline (2005) to evaluate the
effect of ANX-188 at therapeutic and supratherapeutic concentrations on cardiac
repolarization, specifically, Fridericia's QT-Interval (QTcF)
Phase:
Phase 1
Details
Lead Sponsor:
Mast Therapeutics, Inc.
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination